Skip to main content

Advertisement

SpringerLink
Log in

Effects of two different somatostatin analogs on glucose tolerance in acromegaly

  • Original Article
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

Impaired glucose tolerance is present in many acromegalic patients and treatment with somatostatin analogs has variable effects on glycemic control. The aim of this study was to compare the effects of 2 somatostatin analogs on glucose metabolism, lanreotide slow release (L-SR) and octreotide long acting release (O-LAR), in 10 patients with acromegaly (2 of whom with overt Type 2 diabetes mellitus). Glucose and insulin levels in fasting conditions and in response to OGTT, evaluated as AUC, insulin resistance (IR) evaluated by homeostatic model assessment (HOMA-IR), glycosylated hemoglobin (HbA1c), GH, IGF-I, were assessed during L-SR and O-LAR treatment. Mean fasting glucose, glucose response to OGTT and HbA1c levels in 8 non-diabetic patients did not significantly change after L-SR therapy while they all increased after O-LAR treatment (p<0.05 vs baseline and L-SR). Mean HOMA-IR values calculated in acromegalic patients before medical therapy were higher than in normal subjects (p<0.005) and showed a significant decrease during both treatments (p<0.05). In the 2 diabetic acromegalic patients a worsening in glucose metabolism was observed during O-LAR treatment but not during L-SR. GH and IGF-I levels significantly decreased with both drugs and normalized respectively in 38% and 12% with L-SR, 50% and 25% with O-LAR. In conclusion, both drugs decreased IR in acromegalic patients; O-LAR seems to be more detrimental to glucose metabolism than L-SR, despite being more effective in reducing GH and IGF-I levels.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Nabarro J.D.N. Acromegaly. Clin. Endocrinol. 1987, 26: 481–512.

    Article  CAS  Google Scholar 

  2. Melmed S. Acromegaly. N. Engl. J. Med. 1990, 322: 966–977.

    Article  PubMed  CAS  Google Scholar 

  3. Holdaway I.M., Rajasoorya C. Epidemiology of acromegaly. Pituitary 1999, 2: 29–41.

    Article  PubMed  CAS  Google Scholar 

  4. Ho K., Weissberger A., Marbach P., Lazarus L. Therapeutic efficacy of somatostatin analog SMS 201–995 (octreotide) in acromegaly. Ann Intern. Med. 1990, 112: 173–181.

    Article  PubMed  CAS  Google Scholar 

  5. Koop B.L., Harris A.G., Ezzat S. Effect of octreotide on glucose tolerance in acromegaly. Eur. J. Endocrinol. 1994, 130: 581–586.

    Article  PubMed  CAS  Google Scholar 

  6. Arosio M., Macchelli S., Rossi C.M., Casati G., Biella O., Faglia G. Effects of treatment with octreotide in acromegalic patients- a multicenter Italian study. Eur. J. Endocrinol. 1995, 133: 922–928.

    Article  Google Scholar 

  7. Arosio M., Sartore G., Rossi C.M., Casati G., Faglia G., Manzato E. Italian Multicenter Octreotide Study Group. LDL physical properties, lipoprotein and Lp(a) levels in acromegalic patients. Effects of octreotide therapy. Atherosclerosis 2000, 151: 551–557.

    Article  PubMed  CAS  Google Scholar 

  8. Stewart P.M., Kane K.F., Stewart S.E., Lancranjan I., Sheppard M.C. Depot long-acting somatostatin analog is an effective treatment for acromegaly. J. Clin. Endocrinol. Metab. 1995, 80: 3267–3272.

    PubMed  CAS  Google Scholar 

  9. Davies P.H., Stewart P.E., Lancranjan I., Sheppard M.C., Stewart P.M. Long term therapy with long-acting octreotide (Sandostatin LAR) for the management of acromegaly. Clin. Endocrinol. 1998, 48: 311–316.

    Article  CAS  Google Scholar 

  10. Flogstad A.K., Halse J., Bakke S., et al. Sandostatin LAR in acromegalic patients: long term treatment. J. Clin. Endocrinol. Metab. 1997, 82: 23–28.

    Article  PubMed  CAS  Google Scholar 

  11. Giusti M., Gussoni G., Cuttica C., Giordano G. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six months report on an Italian multicenter study. J. Clin. Endocrinol. Metab. 1996, 81: 2089–2097.

    PubMed  CAS  Google Scholar 

  12. Caron P., Morange I., Cogne M., Jaquet P. Three year follow-up of acromegalic patients treated with intramuscolar slow-release Lanreotide. J. Clin. Endocrinol. Metab. 1997, 82: 18–22.

    PubMed  CAS  Google Scholar 

  13. Verhelst J.A., Pedroncelli A.M., Abs R., et al. Slow-release lanreotide in the treatment of acromegaly: a study in 66 patients. Eur. J. Endocrinol. 2000, 143: 577–584.

    Article  PubMed  CAS  Google Scholar 

  14. Turner H.E., Vadivale A., Keenan J., Wass J.A.D. A comparison of lanreotide and octreotide LAR for treatment of acromegaly. Clin Endocrinol. 1999, 51: 275–280.

    Article  CAS  Google Scholar 

  15. Cozzi R., Dallabonzana D., Attanasio R., Barausse M., Oppizzi G. A comparison between octreotide-LAR and lanreotide-SR in the chronic treatment of acromegaly. Eur. J. Endocrinol. 1999, 141: 267–271.

    Article  PubMed  CAS  Google Scholar 

  16. Chanson P., Boerlin V., Ajzenberg C., et al. Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly. Clin. Endocrinol. 2000, 53: 577–586.

    Article  CAS  Google Scholar 

  17. Jenkins P.J., Akker S., Chew S.L., Besser G.M., Monson J.P., Grossman A.B. Optimal dosage interval for depot somatostatin analog therapy in acromegaly requires individual titration. Clin. Endocrinol. 2000, 53: 719–724.

    Article  CAS  Google Scholar 

  18. Kendall-Taylor P., Miller M., Gebbie J., Turner S., Al-Maskari M. Long acting octreotide LAR compared with lanreotide SR in the treatment of acromegaly. Pituitary 2000, 3: 61–65.

    Article  PubMed  CAS  Google Scholar 

  19. The expert committee on the diagnosis and classification of the diabetes mellitus. Committee report. Diabetes Care 1997, 20: 1183–1197.

    Google Scholar 

  20. Segal K.R., Van Loan M., Fitzgerald P.I., Hodgdon J.A., Van Itallie T.B. Lean body mass estimation by bioelectrical impedance analysis: a four-site cross validation study. Am. J. Clin. Nutr. 1988, 47: 7–14.

    PubMed  CAS  Google Scholar 

  21. Pichard C., Kyle U.G., Bracco D., Slosman D.O., Morabia A., Schutz Y. Reference values of fat-free and fat masses by bioelectrical impedance analysis in 3393 healthy subjects. Nutrition 2000; 16: 245–254.

    Article  PubMed  CAS  Google Scholar 

  22. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentration in man. Diabetologia 1985, 28: 412–419.

    Article  PubMed  CAS  Google Scholar 

  23. Haffner S.M., Gonzales C., Miettinen H., Kennedy E., Stern M.P. A prospective analysis of the HOMA model. Diabetes Care 1996, 10: 1138–1143.

    Article  Google Scholar 

  24. The Mexico City Diabetes Study. A prospective analysis of the HOMA model. Diabetes Care 1996, 19: 1138–1143.

    Article  Google Scholar 

  25. Bonora E., Targher G., Alberiche M., et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000, 23: 57–63.

    Article  PubMed  CAS  Google Scholar 

  26. Kasayama S., Otsuki M., Takagi M., et al. Impaired β-cell function in the presence of reduced insulin sensitivity determines glucose tolerance status in acromegalic patients. Clin. Endocrinol. 2000, 52: 549–555.

    Article  CAS  Google Scholar 

  27. Reisine T., Bell G.I. Molecular biology of somatostatin receptors. Endocr. Rev. 1995, 16: 427–444.

    PubMed  CAS  Google Scholar 

  28. Mitra S., Mezey E., Hunyady B., et al. Colocalization of somatostatin receptor sst5 and insulin in rat pancreatic β-cells. Endocrinology 1999, 140: 3790–3796.

    PubMed  CAS  Google Scholar 

  29. Scelles V., Raccah D., Alessi M.C., Vialle J.M., Juhan-Vague I., Vague P. Plasminogen activator inhibitor 1 and insulin levels in various insulin resistance status. Diabetes Metab. 1992, 18: 38–42.

    CAS  Google Scholar 

  30. Moller N., Schmitz O., Joorgensen J.O., et al. Basal and insulin-stimulated substrate metabolism in patients with active acromegaly before and after adenomectomy. J. Clin. Endocrinol. Metab. 1992, 74: 1012–1019.

    PubMed  CAS  Google Scholar 

  31. Brummer R.J.M., Lonn L., Kvist H., Grangard U., Bengtsson B.A., Sjöström L. Adipose tissue and muscle volume determination by computed tomography in acromegaly, before and 1 year after adenomectomy. Eur. J. Clin. Invest. 1993, 23: 199–205.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Endocrine Sciences, University of Milan, Ospedale Maggiore IRCCS, Via F. Sforza 35, 20122, Milan, Italy

    C. Ronchi, P. Epaminonda, V. Cappiello, P. Beck-Peccoz &  M. Arosio

Authors
  1. C. Ronchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. Epaminonda
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. V. Cappiello
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. P. Beck-Peccoz
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. Arosio
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Arosio.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ronchi, C., Epaminonda, P., Cappiello, V. et al. Effects of two different somatostatin analogs on glucose tolerance in acromegaly. J Endocrinol Invest 25, 502–507 (2002). https://doi.org/10.1007/BF03345491

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03345491

Key-words

Search

Navigation